Theralase Announces 2012 Year End Financials

Theralase Advances Therapeutic Laser and Cancer Destruction Technologies

Toronto, Ontario – May 1, 2013, Theralase Technologies Inc. (TSXV: TLT) announced its year end 2012 financial results today.

Total revenue for the twelve month period ended December 31, 2012 dipped slightly to $1,824,313 compared to $2,027,058 for the same period in 2011, a 10% reduction, primarily due to a reduction in laser sales in the US and internationally. In 2012, Theralase focused its efforts on laser sales in Canada for its Therapeutic Laser Technology (TLT) Division and for accelerating the research and development of its patented cancer destruction platform for its Photo Dynamic Therapy (PDT) Division.

Selling expenses decreased by 41%, to $626,380 for the twelve month period ended December 31, 2012 compared to $1,060,288 for the same period in 2011. The percentage decrease was due to decreased spending on salaries, marketing, advertising and travel related expenses, as more focus was paid to completing sales in Canada, than abroad. 

Administrative expenses increased from $1,028,431 for the twelve months ended December 31, 2011 to $1,238,900 for the same period in 2012 representing an increase of 20%. The increase in administrative expenditures was primarily due to increases in the costs associated with stock based compensation.

Research and development costs increased to $873,335 for the year ended December 31, 2012 compared to $759,352 for the previous year, representing a 15% increase, due in part to the costs required to commercialize the TLC-2000 biofeedback laser, but primarily due to research and development costs of the TLC-3000 Photo Dynamic Compound (PDC) cancer and bacteria destruction technology.

The net loss for the year ended December 31, 2012 was $1,509,569, which included $322,915 of net non-cash expenses (amortization, stock-based compensation expense, foreign exchange gain/loss, equipment write-off and lease inducements) compared to a net loss in 2011 of $1,453,974, which included $74,921 of net non-cash expenses.  The increase in net loss is due to  increases in the costs associated with stock based compensation, commercialization of the patented TLC-2000 Biofeedback Therapeutic Laser due for launch in 2013 and primarily due to the research and development of the TLC-3000 Photo Dynamic Compound cancer destruction technology due for completion of the pre-clinical phase by 4Q2013.

Theralase has had many successes in 2012, specifically:

• Preclinical research that confirmed the complete destruction of subcutaneous (under the skin) colon cancer tumours in mouse subjects, which were treated with the Theralase anti-cancer Photo Dynamic Compound (PDC) technology, which have continued to thrive cancer-free for more than 1 year post-treatment without any side effects.
• Bladder cancer named as the principal cancer target
• Theralase’s PDC was found to be 100% effective in destroying bladder cancer tumour cells
• Theralase PDCs have shown an ability to destroy Escherichia Coli (E. coli) and Listeria Monocytogenes (Listeria) bacteria in vitro when light activated
• Theralase establishes laser distributors in the Middle East and China
• Addition of TENS (Transcutaneous Electrical Nerve Stimulation) on select laser models to allow additional CPT billing codes for the US market
• Theralase's innovative anti-cancer PDC technology validated at major international conferences
• Theralase expands intellectual property portfolio with increased patent protection
• Renowned oncologist Dr. Michael Jewett joins Theralase's medical and scientific advisory board

Roger Dumoulin-White, President and CEO of Theralase Technologies Inc. stated, “The Company has completed the research and development of its next generation, patented TLC-2000 Biofeedback Therapeutic Laser and is now preparing for its launch in 4Q2013. In addition, Theralase has made great strides forward in the research and development of its patented Photo Dynamic Compounds (PDCs), indicated for the destruction of specific cancerous tumours. Our first target, bladder cancer, should be ready for human trials as early as 2014. In order to capitalize on this state-of-the-art cancer destruction technology and dramatically increase shareholder value, Theralase is in negotiations with strategic partners focused on the early commercialization of this ground breaking technology.”

About Theralase Technologies Inc.

Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and wound healing. As well, these applications extend to the care of animals by veterinarians. Theralase is currently developing patented Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralase’s proprietary laser technology.

The complete consolidated financial statements and MD&A for twelve months ending December 31, 2012 may be viewed at www.theralase.com  and www.sedar.com .

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information, please contact:

Roger Dumoulin-White,                                                                              

President & CEO                                                                                           

416-699-LASE (5273) ext. 225                                                                                  

rwhite@theralase.com

Kristina Hachey

Chief Financial Officer

416-699-LASE (5273) ext. 224

khachey@theralase.com                                                                             

Greg Bewsh

Director of Investor Relations

416-699-LASE (5273) ext. 258

gbewsh@theralase.com   

Arkady Mandel

Chief Scientific Officer

416-699-LASE (5273) ext. 260

amandel@theralase.com

Theralase Expands Board of Directors with Strong Financing Capabilities

Toronto, Ontario – February 1, 2013 -- Theralase Technologies Inc. (TSX-V: TLT) announced that effective today Mr. Matthew Perraton PFP, FMA, FCSI and Mr. Guy J. Anderson BA, CFP, CIM, FMA, FCSI, MBA have agreed to serve on the company's Board of Directors.

Mr. Perraton and Mr. Anderson join Mr. Donald Moore, Mr. Randy Bruder and Mr. Roger Dumoulin-White on the board and will be instrumental in helping Theralase secure the financing required to fuel Theralase’s growth over the next 5 to 10 years.

Mr. Perraton brings over 13 years of financial experience to Theralase, most recently as a Financial Planner for TD Waterhouse. Prior to his current position, Mr. Perraton held progressively higher positions with BMO Nesbitt Burns and Bank of Nova Scotia.

Mr. Perraton stated that, “I am delighted to join the board at Theralase, as I am absolutely convinced that Theralase is on the right path for shareholder value with both their therapeutic laser technology for healing tissue and their Photo Dynamic Compound (PDC) technology for destroying cancer. Their technology is far superior to anything I have seen on the market and properly financed I see great opportunities for Theralase in the near term”.

Mr. Anderson brings over 16 years of financial experience to Theralase, most recently as a Wealth Management and Personal Finance Advisor with the Investment Planning Counsel. Prior to his current position, Mr. Anderson held progressively higher positions with Franklin Templeton Investments Canada, T.E. Financial and Bank of Nova Scotia.

Mr. Anderson stated that, “I have followed the progress of Theralase over the last 4 to 5 years and have been amazed that the company has been able to advance such cutting-edge technology on a shoe string budget. I join Matt in saying that properly capitalized there is nothing that stands in the way of Theralase’s success. Their technology is not only the best on the market, but their management team has demonstrated an ability to survive in choppy markets and to advance the technology to the point that it is ready to grow in leaps and bounds”.

Roger Dumoulin-White, President and CEO, Theralase Technologies Inc. stated, “I am pleased that Matt and Guy have agreed to serve on our Board of Directors. They both have broad experience in financial management, regulatory compliance and strategic planning and both possess the vision and financial acumen to drive Theralase forward to achieve our full potential. I welcome Matt and Guy to the board and am confident that both will serve the company and the shareholders well during their tenure.”

Mr. Dumoulin-White also stated, “We are all saddened by the loss of our long time board member Mr. John “Jack” Murphy late last year  and we would like to take this opportunity to express our profound condolences to Jack’s family. He was a strong member of our team, an insightful director and always a pleasure to work with. His business judgment and knowledge will be sorely missed”.

About Theralase Technologies Inc.:

Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and wound healing. Theralase is currently developing patented Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralase’s proprietary and patented laser technology.

 For further information please visit www.theralase.com , regulatory filings may be viewed by visiting www.sedar.com.

 

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information

Roger Dumoulin-White                                                                     

President & CEO                    

416-694-7246 ext. 225                                  

rwhite@theralase.com

Kristina Hachey

Chief Financial Officer

416-694-7246 ext. 224

khachey@theralase.com 

Arkady Mandel

Chief Scientific Officer

416-694-7246 ext. 242

amandel@theralase.com

Greg Bewsh

Director of Investor Relations

416-694-7246 ext. 258

gbewsh@theralase.com   

Efficacy of super-pulsed 905 nm Low Level Laser Therapy (LLLT) in the Management of Traumatic Brain Injury (TBI): A Case Study

RESEARCH

Below you will find my paper recently published in the World Journal of Neuro Science. I have treated over 65 patients for headache/migraine symptoms. The Department of Defense (DOD) has asked me to do anything I can to help resolve major healthcare problem (i.e Traumatic Brain Injury (TBI)) which is of course a major concern for the military.  Shortly after that conversation, a patient was presented to me with a TBI as a result of being hit with a lead pipe 3-4 times. His incapacitating headaches were eliminated in just three treatments. 

As a result of this publication and the positive clinical studies out of Massachusetts, four researchers at the University at Buffalo are preparing to start human trials for Alzheimer’s, Concussion (TBI) and Stroke.  We expect these studies to be done before year-end and if successful will be a major breakthrough in medicine, saving the health care system hundreds of billions of dollars. 

William Stephan, M.D. per 1^st Affiliation, Louis J. Banas, B.S., CLT per 1^st Affiliation, Matthew Bennett, M.D. per 2^nd Affiliation, Huseyin Tunceroglu, MSIV per 3^rd Affiliation

1^st Affiliation: William Stephan M.D., LLC, Buffalo, New York

2^nd.  Affiliation: University of Buffalo School of Medicine and Biomedical Sciences, Buffalo, New York

Email: huseyint@buffalo.edu

Received 04 September 2012.

Abstract

Traumatic brain injury is a major health concern worldwide with massive financial and social impact. Conventional treatments primarily focus on the prevention of further damage to the brain parenchyma, while failing to address the already existent symptoms. Previous clinical studies have shown that Low Level Laser Therapy (LLLT)  can significantly reduce pain and induce temporary vasodilation in capillaries, which the authors hypothesize can be used to improve the quality of life in TBI patients by treating their current symptoms, which are predominately migraine-like headaches. This case report illustrates the use of LLLT in the treatment of a patient with a TBI and the great clinical success achieved in the reduction of pain, as measured by VAS - achievable within five treatments of 10 minutes in duration.

Keywords: Traumatic Brain Injury; Low Level Laser Therapy; LLLT; Chronic Migraines; Headaches

1. INTRODUCTION

Traumatic brain injury (TBI) typically occurs when there is any sudden trauma to the skull that induces damage to the brain. There are many causes of TBIs, but unfortunately no documented cures. According to Faul et al., the annual incidence of TBI in the United States is approximately 1.7 million incidents, which account for 30.5% of injury related deaths[1]. The direct and indirect costs of TBI totaled an estimated 76.5 billion dollars in the United States in 2000 [2]. Traumatic brain injuries play a major role in the health care of our nation, especially in our armed forces, where the men and women serving our country are at a higher risk to suffer a TBI.

Treatment is centered on preventing future insult to the brain, but very little can be done to treat the already existing symptoms. These symptoms, as described by the National Institutes of Health, range from mild to severe and include: headaches, nausea, vomiting, confusion, and blurry vision. Current theory on alleviating the symptoms of TBIs is based on reducing inflammatory and oxidative stress and increasing perfusion to support metabolic needs [3]. A study by Naeser et al. looked at the use of Near Infra Red (NIR) light for the treatment of TBI, stroke, and neurodegenerative disease. Their results were very promising, showing that nightly treatments with NIR LED over a period of months to years improved cognitive abilities [4]. Furthermore, they showed that the use of NIR light increased ATP production, caused vasodilation, and improved perfusion. We believe that the superpulsed 905 nm LLLT system employed in this case study operates through similar mechanisms of action and to support our hypothesis we present a case report of a patient with a traumatic brain injury that was treated with the superpulsed 905 nm LLLT system two years after the injury occurred.

2.   CASE REPORT

A 25 year old man with no pertinent past medical history presented as a new patient. His only complaint was chronic debilitating migraines since a traumatic brain injury which occurred in May of 2010. He was attacked and repeatedly hit over the head with a lead pipe, consequently requiring many sutures and leaving a scar on the brain as evidenced by the MRI performed subsequent to the incident. Since the attack, he has been experiencing excruciating migraines daily which he rates at ranging from 7/10 to 10/10 using a Visual Analog Scale (VAS) reference and physically describes them as: throbbing, squeezing sensations located primarily to the occipital region of his skull. He complains of being unable to have a peaceful night of sleep or to participate in play with his four children, the oldest being 9, due to the constant pain and agony he experiences.

After undergoing multiple previous treatment modalities, which included: medications, vitamin supplements, and chiropractic massage therapies, all of which were unsuccessful at alleviating his symptoms, he had all but given up hope. Willing to try anything to rid himself of the chronic pain, he agreed to undergo LLLT treatment. Using a Theralase® superpulsed LLLT medical laser system equipped with a multiple probe handpiece (5 x 905 nm wavelength @ 0 to 100 mW average power per laser diode + 4 x 660 nm wavelength @ 25 mW average power per laser diode), he was given a total of five treatments delivered over a two week period, with the 905 nm laser diodes set to 50 mW average power. The LLLT was targeted to a total of four areas on the scalp for two and a half minutes each: midline occipital region just below the lamboidal suture, superior aspect of the nape to target the Circle of Willis and over the mastoid processes bilaterally. We selected 905nm wavelength based on a previous scientific study that demonstrated that the 905 nm superpulsed wavelength employed by the system was able to increase inducible Nitric Oxide Synthase (iNOS) expression by 700%, as compared to numerous other wavelengths that showed little or no effect [5]. iNOS has been well documented in numerous clinical studies to cause temporary vasodilation by signaling endothelial cells located in capillary walls to become flaccid and relax. Additional studies have shown that 810 nm and 665 nm wavelengths may also be effective, but those specific wavelengths are not able to produce as much iNOS expression, when compared to 905 nm superpulsed technology [6]. An average power for the superpulsed 905 nm laser diodes was initially chosen to be 50mW based on personal experience, but further clinical investigations may uncover more clinically effective average power settings.

Immediately after the first treatment of only ten minutes in duration, the patient reported a 43% reduction in pain, reporting a VAS of 4/10 from a pre-treatment score of 7/10. He stated the throbbing and squeezing nature of his pain had immediately subsided and that all that was left was more of a dull achy pain. He continued with the treatments over the next week and with each new treatment his pain was further reduced. By the end of the course of 5 treatments, his pain had reduced by over 90% and all that remained was a minor ache that was barely even noticeable. Furthermore, he reported no side effects from the treatment except for a slight sensation of warmth over the area where the laser was placed. He was no longer experiencing constant pain; even his children noticed the difference saying that he looked happier. After two years, he was finally able to achieve a good night’s rest.

3.   DISCUSSION

Low Level Laser Therapy (LLLT) has been used in many acute and chronic conditions, but its effectiveness is yet to be fully documented by human clinical trials for migraine, stroke or TBI. Currently Dr. Michael Whalen, working at Massachusetts General Hospital, is conducting controlled studies using a low level laser with the hopes of bringing this new technology into the forefront of neuroscience and medicine. This case study gives one example of how LLLT can be used to treat chronic migraines, specifically those that are a result of traumatic brain injuries. LLLT has been shown to reduce pain and inflammation, create a state of vasodilation by activating the nitric oxide pathway and further even promote angiogenesis. The present theory is that by increasing blood flow to the brain, and subsequently, increasing oxygen delivery to the brain, the symptoms of a migraine can be mitigated. This case differs from previous studies performed using laser therapy to help patients with TBIs in that the type of laser and the settings used were unique. Specifically, unlike the LED light used by Naeser et al., the therapeutic laser we utilized only required five treatments over two weeks to be effective with immediate results after the first treatment.

It is currently unclear whether or not our patient will need maintenance therapy. He was interviewed at two weeks and 5 months post treatment, does carpentry work with his father   and remains symptom free. He is deeply appreciative of the care he was given and continues to enjoy family life which was impossible before LLLT. More research needs to be done, especially controlled double blind studies to further evaluate the full effectiveness and possible side effects of using LLLT in the treatment of TBIs and migraines, but the latest research has shown that LLLT is an extremely safe and effective technology for a wide range of neural and muscular skeletal conditions.

Note: Mr. Banas has successfully treated over 65 migraine patients not all of whom were victims of a TBI

but except for a few instances gave the a patients life changing , significant relief.

REFERENCES

1.            Faul M, X.L., Wald MM, Coronado VG, Traumatic brain injury in the United States: emergency department visits, hospitalizations, and deaths. 2010.

2.            Finkelstein E, C.P., Miller T and associates, The Incidence and Economic Burden of Injuries in the United States. Oxford University Press, 2006.

3.            Sahni, T., et al., Use of hyperbaric oxygen in traumatic brain injury: retrospective analysis of data of 20 patients treated at a tertiary care centre. Br J Neurosurg, 2012. 26(2): p. 202-7.

4.            Naeser, M.A. and M.R. Hamblin, Potential for transcranial laser or LED therapy to treat stroke, traumatic brain injury, and neurodegenerative disease. Photomed Laser Surg, 2011. 29(7): p. 443-6.

5.            Moriyama, Y., et al., In vivo effects of low level laser therapy on inducible nitric oxide synthase. Lasers Surg Med, 2009. 41(3): p. 227-31.

6.            Wu, Q., et al., Low-level laser therapy for closed-head traumatic brain injury in mice: effect of different wavelengths. Lasers Surg Med, 2012. 44(3): p. 218-26.

Efficacy of super-pulsed 905 nm Low Level Laser Therapy (LLLT) in the management of Traumatic Brain Injury

World Journal of Neuroscience, 2012, 2, ***-*** WJNS
Published Online November 2012 (http://www.SciRP.org/journal/wjns/)
Efficacy of super-pulsed 905 nm Low Level Laser Therapy (LLLT) in the management of Traumatic Brain Injury (TBI): A case study
William Stephan1, Louis J. Banas1, Matthew Bennett2, Huseyin Tunceroglu3
1William Stephan M.D., Limited Liability Company (LLC), New York, USA
2Bennett Health and Wellness, New York, USA
3University of Buffalo School of Medicine and Biomedical Sciences, New York, USA
Email: huseyint@buffalo.edu

ABSTRACT
Traumatic brain injury is a major health concern worldwide with massive financial and social impact. Conventional treatments primarily focus on the pre- vention of further damage to the brain parenchyma, while failing to address the already existent symptoms. Previous clinical studies have shown that Low Level Laser Therapy (LLLT) can significantly reduce pain and induce temporary vasodilation in capillaries, which the authors hypothesize can be used to improve the quality of life in TBI patients by treating their current symptoms, which are predominately migraine- like headaches. This case report illustrates the use of LLLT in the treatment of a patient with a TBI and the great clinical success achieved in the reduction of pain, as measured by VAS—achievable within five treatments of 10 minutes in duration.
Keywords: Traumatic Brain Injury; Low Level Laser Therapy; LLLT; Chronic Migraines; Headaches
1. INTRODUCTION
Traumatic brain injury (TBI) typically occurs when there is any sudden trauma to the skull that induces damage to the brain. There are many causes of TBIs, but unfortu- nately no documented cures. According to Faul et al., the annual incidence of TBI in the United States is approxi- mately 1.7 million incidents, which account for 30.5% of injury related deaths [1]. The direct and indirect costs of TBI totaled an estimated 76.5 billion dollars in the United States in 2000 [2]. Traumatic brain injuries play a major role in the health care of our nation, especially in our armed forces, where the men and women serving our country are at a higher risk to suffer a TBI.
Treatment is centered on preventing future insult to the brain, but very little can be done to treat the already ex- isting symptoms. These symptoms, as described by the National Institutes of Health, range from mild to severe and include: headaches, nausea, vomiting, confusion, and blurry vision. Current theory on alleviating the symp- toms of TBIs is based on reducing inflammatory and oxi- dative stress and increasing perfusion to support meta- bolic needs [3]. A study by Naeser et al. looked at the use of Near Infra Red (NIR) light for the treatment of TBI, stroke, and neurodegenerative disease. Their results were very promising, showing that nightly treatments with NIR LED over a period of months to years improved cognitive abilities [4]. Furthermore, they showed that the use of NIR light increased ATP production, caused vaso- dilation, and improved perfusion. We believe that the superpulsed 905 nm LLLT system employed in this case study operates through similar mechanisms of action and to support our hypothesis we present a case report of a patient with a traumatic brain injury that was treated with the superpulsed 905 nm LLLT system two years after the injury occurred.
2. CASE REPORT
A 25-year-old man with no pertinent past medical history presented as a new patient. His only complaint was chronic debilitating migraines since a traumatic brain injury which occurred in May of 2010. He was attacked and repeatedly hit over the head with a lead pipe, cons- quently requiring many sutures and leaving a scar on the brain as evidenced by the MRI performed subsequent to the incident. Since the attack, he has been experiencing excruciating migraines daily which he rates at ranging from 7/10 to 10/10 using a Visual Analog Scale (VAS) reference and physically describes them as: throbbing, squeezing sensations located primarily to the occipital region of his skull. He complains of being unable to have a peaceful night of sleep or to participate in play with his four children, the oldest being 9, due to the constant pain Published Online November 2012 in SciRes. http://www.scirp.org/journal/wjns
2 W. Stephan et al. / World Journal of Neuroscience 2 (2012) **-**
and agony he experiences.
After undergoing multiple previous treatment modali- ties, which included: medications, vitamin supplements, and chiropractic massage therapies, all of which were unsuccessful at alleviating his symptoms, he had all but given up hope. Willing to try anything to rid himself of the chronic pain, he agreed to undergo LLLT treatment. Using a Theralase® superpulsed LLLT medical laser sys- tem equipped with a multiple probe handpiece (5 × 905 nm wavelength @ 0 to 100 mW average power per laser diode + 4 × 660 nm wavelength @ 25 mW average power per laser diode), he was given a total of five treat- ments delivered over a two week period, with the 905 nm laser diodes set to 50 mW average power. The LLLT was targeted to a total of four areas on the scalp for two and a half minutes each: midline occipital region just below the lamboidal suture, superior aspect of the nape to target the Circle of Willis and over the mastoid processes bilate- rally. We selected 905 nm wavelength based on a previ- ous scientific study that demonstrated that the 905 nm superpulsed wavelength employed by the system was able to increase inducible Nitric Oxide Synthase (iNOS) expression by 700%, as compared to numerous other wave-lengths that showed little or no effect [5]. iNOS has been well documented in numerous clinical studies to cause temporary vasodilation by signaling endothelial cells located in capillary walls to become flaccid and relax. Additional studies have shown that 810 nm and 665 nm wavelengths may also be effective, but those specific wavelengths are not able to produce as much iNOS expression, when compared to 905 nm superpulsed technology [6]. An average power for the superpulsed 905 nm laser diodes was initially chosen to be 50 mW based on personal experience, but further clinical inves- tigations may uncover more clinically effective average power settings.
Immediately after the first treatment of only ten min- utes in duration, the patient reported a 43% reduction in pain, reporting a VAS of 4/10 from a pre-treatment score of 7/10. He stated the throbbing and squeezing nature of his pain had immediately subsided and that all that was left was more of a dull achy pain. He continued with the treatments over the next week and with each new treat- ment his pain was further reduced. By the end of the course of 5 treatments, his pain had reduced by over 90% and all that remained was a minor ache that was barely even noticeable. Furthermore, he reported no side effects from the treatment except for a slight sensation of warmth over the area where the laser was placed. He was no longer experiencing constant pain; even his children no- ticed the difference saying that he looked happier. After two years, he was finally able to achieve a good night’s rest.
3. DISCUSSION
Low Level Laser Therapy (LLLT) has been used in many acute and chronic conditions, but its effectiveness is yet to be fully documented by human clinical trials for mi- graine, stroke or TBI. Currently Dr. Michael Whalen, working at Massachusetts General Hospital, is conduct- ing controlled studies using a low level laser with the hopes of bringing this new technology into the forefront of neuroscience and medicine. This case study gives one example of how LLLT can be used to treat chronic mi- graines, specifically those that are a result of traumatic brain injuries. LLLT has been shown to reduce pain and inflammation, create a state of vasodilation by activating the nitric oxide pathway and further even promote an- giogenesis. The present theory is that by increasing blood flow to the brain, and subsequently, increasing oxygen delivery to the brain, the symptoms of a migraine can be mitigated. This case differs from previous studies per- formed using laser therapy to help patients with TBIs in that the type of laser and the settings used were unique. Specifically, unlike the LED light used by Naeser et al., the therapeutic laser we utilized only required five treat- ments over two weeks to be effective with immediate re- sults after the first treatment.
It is currently unclear whether or not our patient will need maintenance therapy. He was interviewed at two weeks and two months post treatment and remains sym- ptom free. He is deeply appreciative of the care he was given and continues to enjoy family life which was impossible before LLLT. More research needs to be done, especially controlled double blind studies to further eva- luate the full effectiveness and possible side effects of using LLLT in the treatment of TBIs and migraines, but the latest research has shown that LLLT is an extremely safe and effective technology for a wide range of neural and muscular skeletal conditions.
REFERENCES
[1]
Faul, M.X.L., Wald, M.M. and Coronado, V.G. (2010) Traumatic brain injury in the United States: Emergency department visits, hospitalizations, and deaths. *, **-**.
[2]
Finkelstein E, C.P., Miller T and associates, The Inci-dence and Economic Burden of Injuries in the United States. Oxford University Press, 2006. doi:10.1093/acprof:oso/9780195179484.001.0001
[3]
Sahni, T., et al., (2012) Use of hyperbaric oxygen in traumatic brain injury: retrospective analysis of data of 20 patients treated at a tertiary care centre. British Journal of Neurosurgery, 26, 202-207. doi:10.3109/02688697.2011.626879
[4]
Naeser, M.A. and Hamblin, M.R. (2011) Potential for transcranial laser or LED therapy to treat stroke, trau- matic brain injury, and neurodegenerative disease. Pho- Copyright © 2012 SciRes. WJNS
W. Stephan et al. / World Journal of Neuroscience 2 (2012) **-**
Copyright © 2012 SciRes. WJNS
3
tomedicine and Laser Surgery, 29, 443-446. doi:10.1089/pho.2011.9908
[5]
Moriyama, Y., et al. (2009) In vivo effects of low level laser therapy on inducible nitric oxide synthase. Lasers in Surgery and Medicine, 41, 227-231. doi:10.1002/lsm.20745

The laser used in this study was the TLC-1000, super-pulsed multi-probe laser
For more information please call 1-866-843-5273 or visit www.theralase.com

Theralase to Present at BioFinance 2012 Life Sciences Conference

Toronto, Ontario – May 29, 2012, Theralase Technologies Inc. (TSXV: TLT) announced today that Roger Dumoulin-White, President and CEO will present the latest corporate information at the BioFinance 2012 conference being held in Toronto, Ontario from May 29 to 30, 2012.

BioFinance is a leading life sciences investor conference in Canada which showcases more than 60 diverse life science companies and the investment opportunities that they present. BioFinance 2012 also features 17 investor presentations that are aimed at addressing specific financing and management related issues relevant to life science industries.

Theralase’s presentation will take place Wednesday, May 30th at 3:00 pm in Company Presentation Room 1 at the St. Andrew’s Club and Conference Center. Mr. Roger Dumoulin-White, President and CEO of Theralase will present on the strategic direction and recent accomplishments of the company followed by a short Q&A period and longer one-on-one meeting period.

In other news, Mr. Dumoulin-White was recently interviewed on the TV show “The Next Biggest Winner” which is due to air on Ichannel on Tuesday, June 5^th at 7:30pm.  The Ichannel has over 1.3 million affluent Canadian subscribers who look to its business programming for investment opportunities. For a sneak preview, please visit http://youtu.be/y8VT6Rwp_gY

About Theralase Technologies Inc.:

Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is internationally approved in the safe and effective treatment of pain, inflammation and for the regeneration of tissue in neural muscular skeletal conditions in both humans and animals. Theralase is also researching and developing patented Photo Dynamic Compound (PDC) technology that is focused at targeting and destroying specific cancers, bacteria and viruses when light activated by Theralase’s proprietary and patented laser technologies.

For further information please visit www.theralase.com, regulatory filings may be viewed by visiting www.sedar.com.

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information, please contact:

Roger Dumoulin - White,                                                                         

President & CEO                                                                                       

416-447-8455 ext. 225                                                                              

rwhite@theralase.com

Kristina Hachey

Chief Financial Officer

416-447-8455 ext. 224

khachey@theralase.com

Theralase Study Points to Cancer Breakthrough

The company's photodynamic therapy treatments destroyed tumors and prevented any recurrence.

Cells living and dead Photodynamic therapy (PDT) is a potential treatment regime for a number of conditions. It involves introducing particular light-sensitive chemical species into biological systems, inducing them to localize at the point of interest, and then irradiating them with a light source. It holds particular promise as a treatment to combat certain cancers, and the latest results from trials using a system developed by Ontario-based Theralase have shown that PDT was able to completely destroy subcutaneous colon cancer tumors in a mouse model. Four weeks after treatment, the mice remained free of cancer. "The achievement of this important milestone signifies that Theralase's leading drug candidate is effective in the destruction of cancer in a live animal model and can prevent the cancer from recurring," commented Roger White of Theralase. "We are confident that Theralase is well positioned to expedite the required steps to initiate human trials in the near future." Those trials could begin as soon as next year. White envisages a clinical road map in which a three-stage program of FDA-moderated human clinical trials could start in 2013, and be completed in 2019. Therapeutic and oncology markets Theralase is a developer of FDA-approved therapeutic medical lasers for treatment of chronic pain, neural muscular skeletal conditions and wound care. But alongside work in these sectors, the company has also patented light-sensitive photodynamic compounds (PDCs) for use in PDT. "The company first entered the PDC space a little less than eight years ago, when it licensed some PDCs from a university researcher, and has been working on developing them since then," White told optics.org. "Theralase is expert at designing, manufacturing and distributing medical laser systems; our PDC researchers are experts at designing and synthesizing PDCs; and colleagues at Princess Margaret Hospital, home of the Ontario Cancer Institute, are experts at testing our PDCs and lasers through in-vitro and in-vivo pre-clinical and eventually clinical models." Despite its simplicity in principle, PDT is not a trivial operation. The treatment is thought to work when the photosensitizer in the tumor absorbs the light and produces an active singlet-state oxygen molecule, an aggressive species which reacts with and kills the tumor cells. But arranging for suitable PDCs to be present and localized in a tumor without being dealt with first by the body's own immune system is a challenge. In addition, only recent developments in endoscopic light-delivery systems have made subcutaneous tumors realistically treatable, and also broadened the range of potential wavelengths and matching photosensitizers. "The wavelength of the source is of course critical, as are the average power, peak power, frequency, fluence and fluence distribution," noted White. "Some of the laser sources used in the research are proprietary to Theralase, and have been custom designed to match the characteristics of the PDCs and hence optimize activation." The two apparently disparate sectors in which Theralase now operates are not so different for the company, according to White, who believes that the expertise gained should stand Theralase in good stead for continuing moves in these and other markets: "The therapeutic market and oncology market are two different animals; however, our experience in working with the medical community prepares us to work in the various disciplines of medicine."

Theralase and George Brown College Join in Government-Funded Research to Combat Food Contamination

Toronto - June 14, 2011 - Theralase Technologies Inc. (TSXV:TLT) announced today that it is partnering with George Brown College’s Centre for Hospitality and Culinary Arts to conduct applied research in the use of patented photodynamic compounds (PDCs) activated by its proprietary laser technology to destroy microbial pathogens associated with food contamination.

This food safety approach, believed to be the first of its kind, is supported by the National Sciences and Engineering Research Council of Canada (NSERC).  PDCs are light sensitive molecules that have the ability to attach themselves to specific cell types, in this case food pathogens such as bacteria, and are able to destroy these cells upon light activation.

Theralase Technologies Inc, founded in Toronto in 1995, designs, develops and manufactures patented, superpulsed laser technology utilized in biostimulation and biodestruction applications.

“In the wake of many outbreaks of consumer food contaminations associated with microbial pathogens such as Listeria monocytogenes (Listeria) and Escherichia coli (E. coli) and their various strains, Theralase initiated the study to determine the feasibility of using our patented PDCs for sanitation in the food service, food manufacturing and medical industries,” said Roger Dumoulin - White, President & CEO of Theralase Inc.  “Given their history and pedigree in culinary arts and additional focus on food applied research, the George Brown College Centre for Hospitality and Culinary Arts is a perfect partner for applied research in new and innovative sanitation protocols and techniques using the company’s patented lasers and photodynamic compounds.”

The 14-week food safety feasibility study will determine the specific areas in food processing facilities where pathogen contamination is not being adequately addressed by current processes and procedures. The contamination danger is a fundamental and ongoing concern of the food industry.

”Food  safety is an increasingly important public health issue as food recalls are a costly exercise that can easily tarnish a company’s reputation of quality. At George Brown we are always looking for relevant initiatives to conduct applied research that can provide our students with real time, real life learning opportunities as well as mutually benefiting our industry partners by providing effective solutions.” said Winnie Chiu, Director, Food Innovation & Research, and Principal Investigator, George Brown College.

The results of the study are expected in September 2011 and will be followed by further lab testing and a pilot project at a commercial food processing facility.  

About Theralase Technologies Inc.

Theralase Technologies Inc. designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. The technology is safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound care. When combined with its patented, light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria and viruses.

About George Brown College

Toronto’s George Brown College has established a reputation for equipping students with the skills, industry experience and credentials to pursue the careers of their choice. From its two main campuses located across the downtown core, George Brown offers nearly 160 programs across a wide variety of professions to a student body of 60,000 (including those enrolled in full-time, part-time and continuing education programs). Students can earn diplomas, post-graduate certificates, industry accreditations, apprenticeships and four-year bachelor degrees. 

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information

Roger Dumoulin-White                                   Robyn Breslow                                  

President & CEO, Theralase                          APEX Public Relations (for George Brown College)

416-447-8455 ext. 225                                    416-924-4442 ext. 256

rwhite@theralase.com                                    rbreslow@apexpr.com

www.theralase.com                                        www.georgebrown.ca

Greg Bewsh

Director of Investor Relations, Theralase

416-447-8455 ext. 262

gbewsh@theralase.com

www.theralase.com